Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Non-Hodgkin 17Lymphoma 17Lymphoma, Large B-Cell, Diffuse 15Lymphoma, Follicular 14Lymphoma, Large-Cell, Immunoblastic 13Precursor Cell Lymphoblastic Leukemia-Lymphoma 12Lymphoma, Mantle-Cell 12Leukemia, Lymphocytic, Chronic, B-Cell 12Burkitt Lymphoma 12Lymphoma, B-Cell, Marginal Zone 10Hodgkin Disease 6Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 5Leukemia 5Ovarian Neoplasms 4Neoplasms 4Lymphoma, Large-Cell, Anaplastic 4Immunoblastic Lymphadenopathy 4Breast Neoplasms 4Neoplasm Metastasis 3Leukemia, Myeloid, Acute 3Carcinoma, Non-Small-Cell Lung 3Waldenstrom Macroglobulinemia 2Triple Negative Breast Neoplasms 2Sezary Syndrome 2Sarcoma 2Pancreatic Neoplasms 2Mycosis Fungoides 2Lymphoma, T-Cell, Cutaneous 2Lung Neoplasms 2Kidney Neoplasms 2

Interventions

midostaurin 2selinexor 1pegfilgrastim 1glofitamab 1Topotecan 1Rituximab 1Prednisone 1Positron Emission Tomography Computed Tomography 1Paclitaxel 1Methylprednisolone 1Immunologic Techniques 1Ifosfamide 1Flow Cytometry 1Etoposide 1Dexamethasone 1Clofarabine 1Carboplatin 1Alemtuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Aggression × Paclitaxel × Lymphoid × Clear all
NCT00038545 2018-10-30

A Phase II Study of Paclitaxel and Topotecan With Filgrastim-SD/01 Support For Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma

M.D. Anderson Cancer Center

Phase 2 Completed
25 enrolled
Lymphoid

Aggression, Lymphoma, Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡